目的：研究分析彩色多普勒超声在乳腺癌新辅助化疗疗效评估中的应用价值。方法回顾性研究2014年5月至2015年5月收治的82例乳腺癌患者临床资料。根据化疗疗效进行分组，完全缓解（ CR）+部分缓解（ PR）组和无明显变化（ SD）+进展（ PD）组。采用彩色多普勒超声观察新辅助化疗前后肿瘤病灶体积及病灶血流情况。结果82例研究对象中，其中有57例化疗有效组（ CR+PR组），25例化疗无效组（ SD+PD组）。两组化疗前乳腺肿瘤体积比较差异无显著性（ P ﹥0.05）；化疗后两组乳腺肿瘤体积均较治疗前明显缩小，差异有显著性（ P ﹤0.05），且CR+PR组肿瘤体积缩小更显著。两组化疗前乳腺内部可见丰富血流信号，以II、III级血流为主。CR+PR组化疗后彩色多普勒超声常表现为乳腺肿瘤内部血流不丰富，以0、I级血流为主，与化疗前相比，差异有显著性（ P ﹤0.05）。SD+PD组化疗后乳腺肿瘤彩色多普勒超声表现与化疗前比较无显著差异（ P ﹥0.05）。结论彩色多普勒超声在乳腺癌新辅助化疗疗效评估中的应用价值比较理想，值得临床推广应用。%Objective To assess the value of color doppler ultrasound applied in neoadjuvant chemotherapy evaluation of breast cancer pa-tients. Methods The clinical data of 82 cases with breast cancer were retrospectively collected from May 2014 to 2015 May. They were divided into( CR)+partial remission( PR)group and no significant change( SD)+progression( PD)group according to chemotherapy efficacy. Color Doppler ultrasonography was used to observe the tumor volume and lesion blood flow before and after neoadjuvant chemotherapy. Results 82 cases were studied in this research,including chemotherapy group(57 cases)and ineffective chemotherapy group(25 cases). The breast tumor volume before chemotherapy between the two groups had no statistically significant difference( P ﹥0. 05). Breast tumor volume after chemotherapy were significantly deduced than that before treatment( P ﹤0. 05),and that in CR+PR group was more significant. In the CR+PR group,the color Doppler ultrasound showed that the blood flow in the breast tumor was not abundant,and the blood flow was mainly 0 and I( P ﹤0. 05). There was no significant difference in color Doppler ultrasonography between before and after chemotherapy in SD+PD group( P ﹥0. 05). Conclusion Color Doppler ultrasonography has important value in the assessment of neoadjuvant chemotherapy in patients with breast cancer.
展开▼
